jasminedavis
The active ingredient in Rybelsus, semaglutide, is already marketed for weight loss under the brand name, Wegoby. This medication was developed after clinical trials showed promising results for the role semaglutide plays in weight loss. A Rybelsus 3 mg weight loss review study in comparison of semaglutide with a placebo found that obese patients lost considerably more weight when taking the medication. Over the 68-week trial, the majority of participants lost over 10% of their body weight, with over half losing more than 15%.
In a distinct clinical study, patients taking a variety of anti-obesity drugs had their weight loss outcomes compared. Comparing participants in the research on semaglutide to those taking these drugs (phentermine, liraglutide, and naltrexone), participants lost less weight.
About
- Username
- jasminedavis
- Joined
- Visits
- 0
- Last Active
- Roles
- Member
Discussions
- This user has not made any discussions yet.